Evaxion A/S (EVAX)
NASDAQ: EVAX · Real-Time Price · USD
4.700
-1.050 (-18.26%)
At close: Dec 19, 2025, 4:00 PM EST
4.750
+0.050 (1.06%)
After-hours: Dec 19, 2025, 6:40 PM EST
Evaxion Revenue
Evaxion had revenue of $7.49M in the quarter ending September 30, 2025, with 148.33% growth. This brings the company's revenue in the last twelve months to $7.65M, up 132.17% year-over-year. In the year 2024, Evaxion had annual revenue of $3.34M with 4,480.82% growth.
Revenue (ttm)
$7.65M
Revenue Growth
+132.17%
P/S Ratio
3.49
Revenue / Employee
$166,304
Employees
46
Market Cap
39.20M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.34M | 3.27M | 4,480.82% |
| Dec 31, 2023 | 73.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
EVAX News
- 12 hours ago - Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2 - GlobeNewsWire
- 13 days ago - Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting - GlobeNewsWire
- 5 weeks ago - Evaxion announce 2026 financial calendar - GlobeNewsWire
- 6 weeks ago - Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 - GlobeNewsWire
- 6 weeks ago - Evaxion A/S (EVAX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Evaxion announces business update and third quarter 2025 financial results - GlobeNewsWire
- 6 weeks ago - Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate - GlobeNewsWire
- 7 weeks ago - Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025 - GlobeNewsWire